Metoprolol Stada (Metoprolol Tartrate)

• Metoprolol Stada, a selective β1‑adrenergic blocker, is used in cardiovascular conditions that involve elevated heart rate or myocardial oxygen demand.
• Hypertension: reduces systolic and diastolic pressure by decreasing cardiac output.
• Angina pectoris: alleviates chest pain by lowering myocardial oxygen consumption.
• Myocardial infarction: improves survival after acute MI by reducing cardiac workload.
• Heart failure: enhances left‑ventricular function and decreases hospitalization risk.
• Cardiac arrhythmias: controls ventricular rate in atrial fibrillation and other rhythm disorders.

• Metoprolol tartrate selectively antagonizes β1‑adrenergic receptors located primarily in cardiac tissue. By blocking catecholamine binding, it diminishes cyclic AMP formation, leading to reduced intracellular calcium influx. The resulting decrease in heart rate (negative chronotropy), contractility (negative inotropy), and conduction velocity (negative dromotropy) lowers myocardial oxygen demand and overall cardiac output. These effects collectively contribute to its antihypertensive, anti‑anginal and antiarrhythmic properties.

Metoprolol Stada may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Fatigue: feeling of tiredness or reduced energy.
• Dizziness: light‑headed sensation, especially on standing.
• Bradycardia: slower than normal heart rate.
• Cold extremities: reduced blood flow to hands and feet.
• Gastrointestinal upset: nausea, abdominal discomfort or diarrhea.

Serious or Rare Side Effects

• Severe bradycardia: heart rate markedly low requiring medical attention.
• Hypotension: significant drop in blood pressure leading to fainting.
• Heart block: impairment of electrical conduction in the heart.
• Bronchospasm: narrowing of airways, particularly in patients with asthma.
• Depression or mood changes: new or worsening depressive symptoms.

When prescribing Metoprolol Stada, clinicians should consider several precautionary measures to ensure safe use.

• Assess cardiac function: evaluate heart rate, blood pressure and conduction before initiation.
• Review respiratory history: avoid use in patients with active bronchospastic disease unless benefits outweigh risks.
• Monitor for diabetes: beta‑blockers may mask hypoglycaemia symptoms; check glucose regularly.
• Caution in renal/hepatic impairment: dose adjustment may be required based on organ function.
• Avoid abrupt discontinuation: taper gradually to prevent rebound tachycardia or hypertension.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Metoprolol Stada can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Combined use with non‑selective β‑blockers: may cause excessive bradycardia or heart block.
• Concomitant calcium channel blockers (e.g., verapamil, diltiazem): increase risk of severe bradycardia and AV block.
• Potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine): raise metoprolol plasma concentrations, enhancing adverse effects.

Moderate Interactions (Monitor Closely)

• Antidiabetic agents (insulin, sulfonylureas): beta‑blockade may mask hypoglycaemia signs.
• Antihypertensive drugs (ACE inhibitors, diuretics): additive blood pressure lowering effect.
• NSAIDs: may reduce antihypertensive efficacy of metoprolol.